- $6.39m
- $4.58m
- $37.32m
- 40
- 58
- 30
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -173.87% | ||
| Return on Equity | -384.98% | ||
| Operating Margin | -46.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.85 | 24.1 | 28.67 | 34.07 | 37.32 | 43.38 | 52.13 | 7.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and is used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 3rd, 2015
- Public Since
- October 14th, 2021
- No. of Shareholders
- 3
- No. of Employees
- 92
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 9,446,197
- Address
- 120 Presidential Way,, Suite 330, WOBURN, 01801
- Web
- https://www.biofrontera-us.com/
- Phone
- +1 7812451325
- Auditors
- Marcum LLP
Latest News for BFRI
Upcoming Events for BFRI
Q1 2025 Biofrontera Inc Earnings Release
Biofrontera Inc Annual Shareholders Meeting
Biofrontera Inc Annual Shareholders Meeting
Q2 2025 Biofrontera Inc Earnings Release
Similar to BFRI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
As of Today at 19:36 UTC, shares in Biofrontera are trading at $0.72. This share price information is delayed by 15 minutes.
Shares in Biofrontera last closed at $0.72 and the price had moved by -59.78% over the past 365 days. In terms of relative price strength the Biofrontera share price has underperformed the S&P500 Index by -63.73% over the past year.
The overall consensus recommendation for Biofrontera is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiofrontera does not currently pay a dividend.
Biofrontera does not currently pay a dividend.
Biofrontera does not currently pay a dividend.
To buy shares in Biofrontera you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.72, shares in Biofrontera had a market capitalisation of $6.39m.
Here are the trading details for Biofrontera:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BFRI
Based on an overall assessment of its quality, value and momentum Biofrontera is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biofrontera is $10.50. That is 1358.33% above the last closing price of $0.72.
Analysts covering Biofrontera currently have a consensus Earnings Per Share (EPS) forecast of -$0.77 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biofrontera. Over the past six months, its share price has underperformed the S&P500 Index by -33.64%.
As of the last closing price of $0.72, shares in Biofrontera were trading -29.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biofrontera PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Biofrontera's directors